Literature DB >> 1371180

Effects of the S2-serotonergic receptor antagonist, ketanserin, on cerulein-induced pancreatitis in the rat.

H Oguchi1, M Terashima, T Koiwai, S Kawa, S Furuta, M Kobayashi, T Homma.   

Abstract

We investigated the effects of ketanserin, a S 2 (5-hydroxytryptamine 2; 5-HT 2)-serotonergic receptor antagonist, on cerulein-induced pancreatitis in the rat. Large pharmacological doses of cerulein induced acute pancreatitis in the rat. Ketanserin reduced the cerulein-induced increase in serum amylase concentration in a dose-dependent manner. Treatment with 10 mg/kg of ketanserin per os markedly improved cerulein-induced pancreatitis and was associated with a significant reduction of the increase in serum amylase concentration. In addition, a very specific serotonin S 2 antagonist, ritanserin which has no antihypertensive effect, also reduced the cerulein-induced increase in the serum amylase concentration. These results suggest that S 2 (5-HT 2) may play a role in pathophysiology of cerulein-induced pancreatitis in the rat.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371180     DOI: 10.1016/0024-3205(92)90476-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.

Authors:  Takeshi Tsujino; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Osamu Togawa; Nobuo Toda; Toshihiko Arizumi; Hirofumi Kogure; Keisuke Yamamoto; Suguru Mizuno; Yoko Yashima; Hiroshi Yagioka; Takashi Sasaki; Saburo Matsubara; Natsuyo Yamamoto; Kenji Hirano; Naoki Sasahira; Minoru Tada; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2012-10-24       Impact factor: 7.527

2.  Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment.

Authors:  Murat Pekgöz
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.